191 related articles for article (PubMed ID: 27227739)
1. Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
Ragazini CS; Bahamondes MV; Prandini TR; Brito MB; Amaral E; Bahamondes L; Duarte G; Quintana SM; Ferriani RA; Vieira CS
Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):285-9. PubMed ID: 27227739
[TBL] [Abstract][Full Text] [Related]
2. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
Vieira CS; Bahamondes MV; de Souza RM; Brito MB; Rocha Prandini TR; Amaral E; Bahamondes L; Duarte G; Quintana SM; Scaranari C; Ferriani RA
J Acquir Immune Defic Syndr; 2014 Aug; 66(4):378-85. PubMed ID: 24798768
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
Edén A; Andersson LM; Andersson O; Flamholc L; Josephson F; Nilsson S; Ormaasen V; Svedhem V; Säll C; Sönnerborg A; Tunbäck P; Gisslén M
AIDS Res Hum Retroviruses; 2010 May; 26(5):533-40. PubMed ID: 20455766
[TBL] [Abstract][Full Text] [Related]
4. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
[TBL] [Abstract][Full Text] [Related]
5. Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
McDonald CR; Conroy AL; Gamble JL; Papp E; Hawkes M; Olwoch P; Natureeba P; Kamya M; Silverman M; Cohan D; Koss CA; Dorsey G; Kain KC; Serghides L
Clin Infect Dis; 2018 Jan; 66(3):428-436. PubMed ID: 29136115
[TBL] [Abstract][Full Text] [Related]
6. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
Scarsi KK; Cramer YS; Rosenkranz SL; Aweeka F; Berzins B; Coombs RW; Coughlin K; Moran LE; Zorrilla CD; Akelo V; Aziz M; Friedman RK; Gingrich D; Swaminathan S; Godfrey C; Cohn SE;
Lancet HIV; 2019 Sep; 6(9):e601-e612. PubMed ID: 31498109
[TBL] [Abstract][Full Text] [Related]
8. Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens.
Kreitchmann R; Stek A; Best BM; Capparelli E; Wang J; Shapiro D; Chakhtoura N; Mirochnick M; Eke AC;
Contraception; 2022 Jan; 105():67-74. PubMed ID: 34407424
[TBL] [Abstract][Full Text] [Related]
9. Low Third-Trimester Serum Levels of Lamivudine/Zidovudine and Lopinavir/Ritonavir in an HIV-Infected Pregnant Woman with Gastric Bypass.
Michalik DE; Jackson-Alvarez JT; Flores R; Tolentino-Baldridge C; Batra JS
J Int Assoc Provid AIDS Care; 2015; 14(2):116-9. PubMed ID: 25361558
[TBL] [Abstract][Full Text] [Related]
10. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
Rojas J; Lonca M; Imaz A; Estrada V; Asensi V; Miralles C; Domingo P; Montero M; del Rio L; Fontdevila J; Perez I; Cruceta A; Gatell JM; Arnedo M; Martínez E
HIV Med; 2016 May; 17(5):340-9. PubMed ID: 27089862
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
Gleason RL; Caulk AW; Seifu D; Rosebush JC; Shapiro AM; Schwartz MH; Eckard AR; Amogne W; Abebe W
J Biomech; 2016 Sep; 49(13):2584-2592. PubMed ID: 27270208
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.
Pulido F; Estrada V; Baril JG; Logue K; Schewe K; Plettenberg A; Duiculescu D; Yau L; Vavro C; Lim ML; Pharo C
HIV Clin Trials; 2009; 10(2):76-87. PubMed ID: 19487177
[TBL] [Abstract][Full Text] [Related]
14. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
[TBL] [Abstract][Full Text] [Related]
15. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
Koss CA; Natureeba P; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Clark TD; Achan J; Ruel T; Nzarubara B; Kamya MR; Havlir DV; Cohan D
J Acquir Immune Defic Syndr; 2014 Oct; 67(2):128-35. PubMed ID: 25072616
[TBL] [Abstract][Full Text] [Related]
17. High Variability of Hormonal Levels and No Clinically Relevant Interaction Between Ethinyl Estradiol, Desogestrel and Lopinavir/Ritonavir in a Small Sample of HIV-positive Adolescents.
Kancheva Landolt N; Bunupuradah T; Kosalaraksa P; Ubolyam S; Thammajaruk N; Cremers S; Zott R; Kerr S; Ananworanich J;
J Acquir Immune Defic Syndr; 2016 Aug; 72(5):507-12. PubMed ID: 26990825
[TBL] [Abstract][Full Text] [Related]
18. Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
Gleason RL; Caulk AW; Seifu D; Parker I; Vidakovic B; Getenet H; Assefa G; Amogne W
PLoS One; 2015; 10(4):e0117125. PubMed ID: 25915208
[TBL] [Abstract][Full Text] [Related]
19. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
20. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
